---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-024812"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:37:38.683129+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharma CFO Nathan Fuentes resigns; Michelle Yanez appointed CFO

## Summary
- CFO Nathan Fuentes resigned June 18, 2024; separation includes $62,500 over 3 months and option extension.
- Michelle Yanez, MBA, appointed CFO effective June 18; was part-time Corporate Controller since May 2022.
- Yanez also serves as CFO of MIRA Pharmaceuticals (Nasdaq: MIRA); base salary $137,500/yr.
- Yanez receives sign-on bonus tied to change of control, discretionary annual bonus, no upfront equity.
- Resignation was not based on any disagreement with Company's operations, policies, or practices.

## SEC filing metadata
- accession: 0001493152-24-024812
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315224024812/0001493152-24-024812-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315224024812/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-024812
- JSON: https://secwatch.observer/filing/0001493152-24-024812.json
- Plain text: https://secwatch.observer/filing/0001493152-24-024812.txt

## Key facts
- Executive change
  Nathan Fuentes resigned as Chief Financial Officer at Telomir Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On June 18, 2024, Telomir Pharmaceuticals, Inc. (the “ Company ”) and Nathen Fuentes entered into a Confidential Separation and Mutual General Release Agreement (the “ Separation Agreement ”) whereby both the Company and Mr. Fuentes mutually agreed that Mr. Fuentes’ employment as a Chief Financial Officer of the Company would end as of June 18, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971532/000149315224024812/0001493152-24-024812-index.htm
- Executive change
  Michelle Yanez was appointed as Chief Financial Officer at Telomir Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On June 18, 2024, the Board of the Company appointed Michelle Yanez, MBA as the Chief Financial Officer, of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971532/000149315224024812/0001493152-24-024812-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.